Statins do not prevent acute organ failure in ventilated ICU patients: single-centre retrospective cohort study

Table 2 Unadjusted outcome data

Variable	Overall (n= 1397)	Nonstatin group (n= 1,178)	Statin group (n= 219)	P value
Organ failure
On or after day of first statin administration	359/1,376 (26.1%)	292/1,178 (24.8%)	67/198 (33.8%)	0.007
At least 1 day after first statin administration	344/1,361 (25.3%)	292/1,178 (24.8%)	52/183 (28.4%)	0.29
Days to organ failure	3 (2, 5) (n = 359)	3 (2, 5) (n = 292)	3 (3, 4) (n = 67)	0.63
Duration of organ failure^a	2 (1, 5) (n = 359)	2 (1, 5) (n = 292)	2 (1, 5) (n = 67)	0.77
Safety
Hepatic failure^b	112/1,392 (8.0%)	89/1,178 (7.6%)	23/214 (10.8%)	0.11
Days to hepatic failure	4 (3,8) (n = 112)	5 (3, 8) (n = 89)	4 (3, 6) (n = 23)	0.46
Duration of hepatic failure	1.5 (1, 3) (n = 112)	2 (1, 3) (n = 89)	1 (1, 4) (n = 23)	0.84
ALT > 165 IU/l^c	77/1,313 (5.9%)	54/1,115 (4.8%)	23/198 (11.6%)	0.0002
Days to ALT > 165 IU/l	7 (4, 11) (n = 77)	6 (4, 11) (n = 54)	8 (5, 12) (n = 23)	0.35
Duration of ALT > 165 IU/l	3 (1, 4) (n = 77)	2 (1, 4) (n = 54)	3 (1, 4) (n = 23)	0.66
Maximum ALT	35 (19, 73) (n = 1,292)	33 (18, 69) (n = 1,094)	50 (28, 110) (n = 198)	< 0.0001
Other outcomes
ICU mortality	177/1,397 (12.7%)	149/1,178 (12.7%)	28/219 (12.8%)	0.96
Hospital mortality	270/1,397 (19.3%)	221/1,178 (18.8%)	49/219 (22.4%)	0.21
ICU length of stay	5 (3, 10) (n = 1,397)	4 (3, 9) (n = 1,178)	7 (4, 15) (n = 219)	< 0.0001
Hospital length of stay	15 (8, 33) (n = 1,397)	14 (7, 31) (n = 1,178)	21 (12, 43) (n = 219)	< 0.0001

Data expressed as mean ± standard deviation, median (interquartile range), or number (percentage). ALT, alanine transferase; ICU, intensive care unit. ^aIncludes four patients in the statin group who had a Sequential Organ Failure Assessment (SOFA) score (hepatic) ≥3 on the day of first statin administration. ^bNew hepatic failure on the day of or after the first day of statin administration (defined as hepatic SOFA score ≥3) or an increase of bilirubin by ≥1.5 times from baseline to a value ≥20 mmol/l. Missing bilirubin values were assumed to be normal. ^cExcludes those in statin group with ALT > 165 IU/l at baseline or occurring before the first statin administration. Missing ALT values were assumed to be normal.

ISSN: 1364-8535